Eli Lilly and Company (NYSE:LLY) announced on Tuesday that the pharmaceuticals company expects Q4 2024 revenue to be ~$13.5B. The consensus revenue estimate stands at $13.95B. "While the U.S ...

"2024 was a pivotal and highly successful year for Lilly, and we expect to continue our momentum in 2025 with strong financial and operational performance," continued Ricks. "Sales of Mounjaro and ...

Interested in working for Housing and Residence Life? Housing and Residence Life at DePauw University seeks to hire a diverse group of student leaders for the 2025-2026 Resident Assistant (RA) team.

For nearly a decade, Eli Lilly has been operating a global capability center (GCC) in Bengaluru, India. Now, with its business booming, the company is setting up a similar site 10 hours to the ...

Steven Gerrard’s daughter Lilly-Ella has revealed she is expecting a baby with Lee Byrne, the son of Dublin gang boss Liam Byrne. Lilly (20) and Crumlin native Lee have been dating for over two ...

The former Liverpool and England ace has four children with wife Alex - daughters Lilly, Lexie, 18, Lourdes, 13, and a son named Lio, eight. Responding to his daughter's post, he wrote ...

Steven Gerrard's eldest daughter, Lilly-Ella, has announced she is pregnant with her first child with boyfriend Lee Byrne, who is the son of a jailed gangster. The 20-year-old shared a photo of ...

In “Lilly,” writer-director Rachel Feldman follows the era-defining work of one such everyday woman: trailblazer Lilly Ledbetter, a pioneer from humble beginnings who took her employer ...

Led by two $1 billion gifts for medical education, 2024 saw more than a dozen colleges & universities receive donations of $100 million or more. Here's a quick review.

Lilly, which is on track to come out as 2024’s 11th largest drugmaker by prescription sales, is expected to climb the ranks to the fourth position in 2025, Evaluate said in its report.

Since Zepbound was approved by the FDA to treat obesity in late 2023, its maker Eli Lilly has been steadily closing in on fierce rival Novo Nordisk’s early lead in the obesity market.

Lilly seeks to protect interests in compounded drug case FDA affirms no shortage of tirzepatide drugs Compounded versions cheaper, often not covered by insurers Jan 2 (Reuters) - Eli Lilly (LLY.N ...